Wet AMD Market Snapshot: A High-Growth Market Poised For Change

 
• By Jessica Merrill

Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.

blue eye
The market for eye treatments is poised for new competition • Source: Alamy

More from Sensory

More from Therapy Areas